If you work with a covered entity, last year’s rules about the 340B Drug Pricing program may not hold for long. Manufacturers are tightening access, regulators are testing new payment models, and the courts and Congress are weighing questions that reach the program’s foundation. Each shift affects cash flow, compliance workload, and the savings that fund patient care.
The purpose of 340B hasn’t changed since 1992. Drug manufacturers, not taxpayers, fund the program. Covered entities reinvest the savings in free or low-cost medications, mental health care, trauma services, and specialty HIV treatment. Capturing those savings, however, is getting harder, and oversight itself may soon move from the Health Resources and Services Administration (HRSA) to the Centers for Medicare and Medicaid Services (CMS), which could bring new rules, new reporting expectations, and new interpretations of existing requirements.
Every development below plays out against that backdrop, so the program may look different in 2027 from the one you know today.
Contract Pharmacy Restrictions Keep Expanding
More than 44 manufacturers now limit 340B pricing at contract pharmacies. At least 13 have extended those limits to entity-owned pharmacies.
These restrictions hit patients first. People in pharmacy deserts struggle to fill 340B-eligible prescriptions close to home. Covered entities also lose savings they depend on. When manufacturers restrict where 340B pricing applies, they shrink the pool of savings available for patient care. Litigation over manufacturer policies and state contract pharmacy laws continues, so expect these rules to keep shifting and plan for regular policy reviews.
Manufacturer Data Demands are Growing
- In-house pharmacy claims
- Medical claims
- Patient encounter and diagnosis information
Deadlines add pressure. Some manufacturers require submissions within 45 days. Others use unpublished timeframes that leave you guessing. Miss a window, even during a system conversion, and you can lose 340B pricing.
To protect pricing, review new manufacturer policies as soon as they’re released. Align purchasing and wholesaler accounts, and keep eligible claim submissions current and documented.
HRSA Rebate Pilot Launch in Question
The HRSA rebate pilot is the most significant change on the horizon, with potential impacts to how entities receive their 340B savings. It initially covers 17 drugs – a list that was recently reduced – but expect it to grow in future years.
- The drug is bought at wholesale acquisition cost (WAC), a dramatically higher price.
- Then, the covered entity has 45 days to submit data for a rebate.
- The manufacturer has ten days after a completed submission to pay a rebate equal to WAC minus the 340B price.
The model raises two concerns. First, it requires fronting the full cost of expensive drugs, which strains cash flow for smaller organizations. Second, it shifts much of the power to decide whether a claim qualifies from providers to manufacturers.
However, the pilot’s path to launch is also far from settled. HRSA released ten approved manufacturer rebate plans on Oct. 1, and within days, lawmakers and hospitals moved to stop or delay the program. On Oct. 9, a bipartisan group of lawmakers introduced a new bill – the 340B Rebate Model Delay Act – which would delay the pilot until Dec. 31, 2028. The same day, the American Hospital Association (AHA), the Maine Hospital Association, and four hospitals filed a complaint in the U.S. District Court in Maine to strike down the pilot. The group also filed a motion for a temporary restraining order to halt the pilot before Jan. 1, 2027.
This isn’t the first round. The same Maine court blocked HRSA’s original rebate pilot from taking effect on Jan. 1, 2026 after a lawsuit from the same two associations and three of the same hospitals, leading to HRSA withdrawing that pilot and unveiling a revamped version. The new complaint argues HRSA violated administrative law by underestimating the pilot’s administrative and financial burdens on covered entities. According to the hospitals, HRSA dismissed providers’ concerns while accepting manufacturers’ claims at face value.
For now, Jan. 1. 2027 remains the start date. A court order or new law could change that, but covered entities should plan as if the pilot will launch on schedule and should stay ready to adjust if it doesn’t.
AbbVie Lawsuit Targets the Patient Definition
A federal lawsuit filed by drug manufacturer AbbVie is currently challenging how the 340B patient definition is applied. The definition determines whether a patient’s prescription qualifies for 340B pricing, and AbbVie argues the program has been applied too broadly, covering patients who don’t have a sufficiently direct, ongoing relationship with a covered entity.
This dispute matters because the patient definition isn’t specific to one drug or one company. It governs how every covered entity qualifies every prescription across the entire program. If the courts side with AbbVie, a narrower standard could apply universally, limiting which claims are eligible regardless of the drug, the manufacturer, or the pharmacy filling the prescription.
Taken together, these developments put pressure on 340B savings from every direction. The good news: there are practical steps that can be taken now to protect them.
Three Strategies to Navigate the Changes
- Forecast rebate pilot impact: Look at how buying pilot drugs at WAC affects cash flow so you can plan before Jan. 1, 2027 – not after. Build two scenarios, one where the pilot launches on time and one where it is delayed, so you’re ready either way.
- Compare 340B savings and PBM rebates: 340B pricing usually beats the PBM pricing net of rebates, but not always. 340B prices change every quarter, and a few drugs carry rebates that exceed 340B savings. When the rebate wins, the 340B submission process can be skipped, and the rebate can be taken instead.
- Optimize the in-house pharmacy: A pharmacy solutions tool matches plan claims to prescribers and pharmacies to find leakage, where members fill outside their 340B relationships. Capturing claims on the entity’s most-used drugs can result in significant savings.
340B will keep changing. Restrictions, data demands, the rebate pilot, and pending litigation and legislation all point toward more complexity, not less.
The programs that fare best stay informed, document their decisions, and analyze every drug for the lowest net cost. By planning ahead instead of reacting, covered entities can protect the savings that keep care within reach for the patients who need it most.
